Actively Recruiting
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Led by Novartis Pharmaceuticals · Updated on 2026-04-06
30
Participants Needed
6
Research Sites
363 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to describe the safety profile of fingolimod in the Taiwanese multiple sclerosis population. This study aims to collect the safety data in patients newly initiated on fingolimod for one year.
CONDITIONS
Official Title
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with relapsing-remitting multiple sclerosis who have not previously been treated with fingolimod
- Patients newly starting fingolimod treatment based on physician judgment and Taiwan's fingolimod package insert (version TWI-090420)
You will not qualify if you...
- Diagnosis of neuromyelitis optica
- Currently treated with any investigational drug
- Experienced myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure in the last 6 months
- History or presence of Mobitz Type II second-degree or third-degree atrioventricular block or sick sinus syndrome without a functioning pacemaker
- Baseline QTc interval of 500 msec or more
- Cardiac arrhythmias requiring Class Ia or Class III anti-arrhythmic drugs
- Known immune deficiency, increased risk of opportunistic infection, severe active infection, or chronic active infection
- Severe active malignancies, except basal cell epithelioma
- Severe hepatic insufficiency
- Pregnant or nursing women, or women of childbearing potential not using contraception
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Novartis Investigative Site
Kaohsiung City, Taiwan, 83301
Actively Recruiting
2
Novartis Investigative Site
Taichung, Taiwan, 407219
Actively Recruiting
3
Novartis Investigative Site
Tainan, Taiwan, 704302
Withdrawn
4
Novartis Investigative Site
Taipei, Taiwan, 10002
Actively Recruiting
5
Novartis Investigative Site
Taipei, Taiwan, 11220
Withdrawn
6
Novartis Investigative Site
Taoyuan, Taiwan, 33305
Withdrawn
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here